Astellas Pharma (OTCMKTS:ALPMY) Lowered to “Hold” Rating by Citigroup

Citigroup lowered shares of Astellas Pharma (OTCMKTS:ALPMY) from a strong-buy rating to a hold rating in a research note issued to investors on Monday morning,Zacks.com reports.

Separately, Zacks Research downgraded Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 22nd. Three analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the company has a consensus rating of “Hold”.

Astellas Pharma Trading Up 0.3%

OTCMKTS ALPMY opened at $14.03 on Monday. Astellas Pharma has a 52 week low of $8.37 and a 52 week high of $14.72. The business’s fifty day simple moving average is $13.25 and its 200-day simple moving average is $11.65. The company has a current ratio of 1.03, a quick ratio of 0.80 and a debt-to-equity ratio of 0.20.

Astellas Pharma (OTCMKTS:ALPMY) last released its earnings results on Thursday, October 30th. The company reported $0.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.20 by $0.10. Astellas Pharma had a net margin of 6.39% and a return on equity of 22.21%. The business had revenue of $3.45 billion for the quarter, compared to analysts’ expectations of $3.14 billion. On average, equities research analysts predict that Astellas Pharma will post 0.42 EPS for the current year.

About Astellas Pharma

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).